HTG’s extraction-free, targeted next-generation sequencing technology adopted to support the IOR’s research and clinical trials in hematological cancers and solid tumors HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (“HTG”), a provider of instruments, reagents, and services for molecular profiling applications, today announced that the Institute of Oncology Research (“IOR”) is now running the HTG EdgeSeq technology … Continue reading HTG Molecular Diagnostics Announces the Institute of Oncology Research Has Adopted the HTG EdgeSeq Technology in its Genomics Facility